Galapagos NV
GLPG
查看详细走势图
33.030USD
+0.040+0.12%
收盘 12/26, 16:00（美东）报价延迟15分钟
2.18B总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+0.12%
5天
+2.07%
1月
+6.10%
6月
+17.67%
今年开始到现在
+20.11%
1年
+20.64%
查看详细走势图
TradingKey Galapagos NV股票评分
单位: USD 更新时间: 2025-12-26操作建议
Galapagos NV当前公司基本面数据相对稳定，增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名102/404位。机构持股占比非常高，近一月多位分析师给出公司评级为卖出。最高目标价27.33。中期看，股价处于平稳状态。近一个月，市场表现较强，技术面和基本面综合得分较高，较强的走势得到基本面和技术面的印证。目前股价在压力位和支撑位之间，可以做区间波段操作。
Galapagos NV评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
5
位分析师
卖出
评级
27.333
目标均价
-13.20%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Galapagos NV亮点
亮点风险
Galapagos NV is a Belgium-based clinical-stage biotechnology company. The Company is engaged in the discovery and development of small molecule medicines with modes of action. Its pipeline comprises Phase 3, 2, 1, pre-clinical studies and discovery small-molecule and antibody programs in cystic fibrosis, inflammation, and other indications. The Company focuses on developing a portfolio of clinical-stage therapies for the enhancement of existing treatment paradigms. It develops transformational medicines in areas of high unmet need by combining internal with external science with the goal to add years of life and improve of life of patients across the globe. It discovers which proteins that are involved in causing diseases such as, rheumatoid, arthritis, inflammatory bowel disease and fibrosis. The Company acquired CellPoint and AboundBio in order to develop a cell therapy, which is a potential transformative treatment of different types of cancer.
Galapagos NV新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Galapagos NV简介
Galapagos NV is a Belgium-based clinical-stage biotechnology company. The Company is engaged in the discovery and development of small molecule medicines with modes of action. Its pipeline comprises Phase 3, 2, 1, pre-clinical studies and discovery small-molecule and antibody programs in cystic fibrosis, inflammation, and other indications. The Company focuses on developing a portfolio of clinical-stage therapies for the enhancement of existing treatment paradigms. It develops transformational medicines in areas of high unmet need by combining internal with external science with the goal to add years of life and improve of life of patients across the globe. It discovers which proteins that are involved in causing diseases such as, rheumatoid, arthritis, inflammatory bowel disease and fibrosis. The Company acquired CellPoint and AboundBio in order to develop a cell therapy, which is a potential transformative treatment of different types of cancer.
公司代码GLPG
公司Galapagos NV
CEOGosebruch (Henry)
网址https://www.glpg.com/
常见问题
Galapagos NV(GLPG)的当前股价是多少？
Galapagos NV(GLPG)的当前股价是 33.030。
Galapagos NV的股票代码是什么？
Galapagos NV的股票代码是GLPG。
Galapagos NV股票的52周最高点是多少？
Galapagos NV股票的52周最高点是37.780。
Galapagos NV股票的52周最低点是多少？
Galapagos NV股票的52周最低点是22.360。
Galapagos NV的市值是多少？
Galapagos NV的市值是2.18B。
Galapagos NV的净利润是多少？
Galapagos NV的净利润为74.08M。
现在Galapagos NV(GLPG)的股票是买入、持有还是卖出？
根据分析师评级，Galapagos NV(GLPG)的总体评级为卖出，目标价格为27.333。
Galapagos NV(GLPG)股票的每股收益（EPS TTM）是多少
Galapagos NV(GLPG)股票的每股收益（EPS TTM）是-5.639。
相关品种
